[Long-term treatment of mucoviscidosis. Results with a microencapsulated pancreatic enzyme preparation].
METHODS
In 30 children suffering from cystic fibrosis, the long-term effect (2 years) of treatment with an acid-protected micro-encapsulated pancreatin preparation was investigated in comparison with prior enzyme replacement with a conventional pancreatin preparation given over a period of years. Assessment criteria was the development of body length and body weight, lung function (vital capacity, FEF1) and the Shwachman-Kulczycki score.


RESULTS
The therapeutic efficacy of the acid-protected micro-encapsulated preparation is considered to be higher than that of conventional preparations, since the same effect was achieved with only one-quarter to one-third of the pancreatin dose of the conventional preparation (average: 6.5 +/- 2.9 g pancreatin/d, as compared with 1.6 +/- 0.6 g pancreatin in the case of the acid-protected micro-encapsulated preparation). However, none of the clinical parameters investigated revealed any significant changes during the course of the observation period. The results indicate that, if the general state of health and nutritional status of patients with cystic fibrosis is to be improved further, in addition to a special diet, attempts must be made to achieve further optimization of the intraluminal digestion.
Henker
J
J
Klinik für Kinderheilkunde, Medizinische Akademie, Dresden.
Hoffmann
D
D
Paul
D
D
Hein
J
J
Paditz
E
E
D000293:Adolescent; D002214:Capsules; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008049:Lipase / Q000008:administration & dosage*; D008134:Long-Term Care; D008297:Male; D010184:Pancreatic Extracts / Q000008:administration & dosage*; D010194:Pancreatin / Q000008:administration & dosage*; D020799:Pancrelipase
D002214:Capsules; D010184:Pancreatic Extracts; D020799:Pancrelipase; D010194:Pancreatin; D008049:Lipase